An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
for Breast Cancer, Early Breast Cancer
Drug: Camizestrant
148 locations incl. Dothan
Sponsor: AstraZeneca
Sex: All·Age: 18 - 130
Code: NCT05952557·Phase 3·Recruiting